BACKGROUND: Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. METHODS: Eligible patients had primary or recurrent muscle-invasive disease with transitional cell or squamous cell histology, a performance status from 0 to 2, no extrapelvic disease, a life expectancy >3 months, and adequate hematologic function. The treating clinician assigned patients to operable or inoperable groups. All patients received 2 cycles of 5-fluorouracil (5-FU) at a dose of 1000 mg/m(2) per day x 4 starting concurrently with radiation at a dose of 200 centigrays per day x 10 each cycle. After 2 cycles, operable patients with positive biopsies underwent cystectomy, and patients with negative biopsies received a third cycle of chemoradiotherapy. Patients in the inoperable group received 3 cycles without interim biopsy. RESULTS: Eighteen of 24 eligible patients in the operable group were evaluable for response. Five patients had a complete response (CR), 9 patients had stable disease, 1 patient had progressive disease, and 3 patients were not assessable. The median progression-free survival was 10 months (95% confidence interval [95% CI], 4-14 months), and the median overall survival was 18 months (95% CI, 7-28 months). In the inoperable group, 35 of 37 eligible patients were evaluable for response with 17 CRs (49%; 95% CI, 31%-66%). The median progression-free survival was 13 months (95% CI, 10-17 months), and the median overall survival was 20 months (95% CI, 11-53 months). There were no episodes of grade 4 toxicity. CONCLUSIONS: In the current study, the combination of 5-FU and radiation was found to be tolerated well by patients with numerous comorbidities who could not tolerate cisplatin-based therapy or cystectomy. (c) 2008 American Cancer Society.
BACKGROUND: Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. METHODS: Eligible patients had primary or recurrent muscle-invasive disease with transitional cell or squamous cell histology, a performance status from 0 to 2, no extrapelvic disease, a life expectancy >3 months, and adequate hematologic function. The treating clinician assigned patients to operable or inoperable groups. All patients received 2 cycles of 5-fluorouracil (5-FU) at a dose of 1000 mg/m(2) per day x 4 starting concurrently with radiation at a dose of 200 centigrays per day x 10 each cycle. After 2 cycles, operable patients with positive biopsies underwent cystectomy, and patients with negative biopsies received a third cycle of chemoradiotherapy. Patients in the inoperable group received 3 cycles without interim biopsy. RESULTS: Eighteen of 24 eligible patients in the operable group were evaluable for response. Five patients had a complete response (CR), 9 patients had stable disease, 1 patient had progressive disease, and 3 patients were not assessable. The median progression-free survival was 10 months (95% confidence interval [95% CI], 4-14 months), and the median overall survival was 18 months (95% CI, 7-28 months). In the inoperable group, 35 of 37 eligible patients were evaluable for response with 17 CRs (49%; 95% CI, 31%-66%). The median progression-free survival was 13 months (95% CI, 10-17 months), and the median overall survival was 20 months (95% CI, 11-53 months). There were no episodes of grade 4 toxicity. CONCLUSIONS: In the current study, the combination of 5-FU and radiation was found to be tolerated well by patients with numerous comorbidities who could not tolerate cisplatin-based therapy or cystectomy. (c) 2008 American Cancer Society.
Authors: B J Jenkins; M J Caulfield; C G Fowler; D F Badenoch; R C Tiptaft; A M Paris; H F Hope-Stone; R T Oliver; J P Blandy Journal: Br J Urol Date: 1988-10
Authors: Vijay K Sangar; Catherine A McBain; Jeanette Lyons; Vijay A C Ramani; John P Logue; James P Wylie; Noel W Clarke; Richard A Cowan Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: K J Russell; M A Boileau; C Higano; C Collins; A H Russell; W Koh; S B Cole; W H Chapman; T W Griffin Journal: Int J Radiat Oncol Biol Phys Date: 1990-09 Impact factor: 7.038
Authors: M K Gospodarowicz; N V Hawkins; G A Rawlings; J G Connolly; M A Jewett; G M Thomas; J G Herman; P G Garrett; T Chua; W Duncan Journal: J Urol Date: 1989-12 Impact factor: 7.450
Authors: M H Hussain; T R Glass; J Forman; W Sakr; D C Smith; M Al-Sarraf; J Jones; S P Balcerzak; E D Crawford; H B Grossman Journal: J Urol Date: 2001-01 Impact factor: 7.450
Authors: M Rotman; H Aziz; M Porrazzo; K N Choi; M Silverstein; J Rosenthal; G Laungani; R Macchia Journal: Int J Radiat Oncol Biol Phys Date: 1990-05 Impact factor: 7.038
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Jeremy W Martin; Estrella M Carballido; Ahmed Ahmed; Bilal Farhan; Rahul Dutta; Cody Smith; Ramy F Youssef Journal: Arab J Urol Date: 2016-08-01